Xilio’s New IND Tests Whether Masked IL-2 Can Make Immunotherapy Safer in Solid Tumors
The U.S. Food and Drug Administration has cleared Xilio Therapeutics to begin human testing of XTX501, a bispecific PD-1 and…
Decoding the Science of Life